44.19
1.11%
-0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$44.64
Aprire:
$44.4
Volume 24 ore:
2.35M
Capitalizzazione di mercato:
$90.47B
Reddito:
$45.53B
Utile/perdita netta:
$-6.15B
Rapporto P/E:
11.22
EPS:
3.94
Flusso di cassa netto:
$12.51B
1 W Prestazione:
-9.89%
1M Prestazione:
-18.60%
6M Prestazione:
-13.86%
1 anno Prestazione:
-33.88%
Bristol-Myers Squibb Co. Stock (BMY) Company Profile
Nome
Bristol-Myers Squibb Co.
Settore
Industria
Telefono
212-546-4000
Indirizzo
345 Park Avenue, New York, NY
Bristol-Myers Squibb Co. Stock (BMY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2023-11-09 | Iniziato | Deutsche Bank | Hold |
2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
2023-10-20 | Ripresa | UBS | Neutral |
2023-07-14 | Iniziato | HSBC Securities | Reduce |
2023-07-10 | Iniziato | SVB Securities | Market Perform |
2023-06-28 | Iniziato | Daiwa Securities | Outperform |
2023-03-06 | Iniziato | Jefferies | Hold |
2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
2022-11-18 | Iniziato | Credit Suisse | Neutral |
2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
2022-09-14 | Downgrade | Berenberg | Buy → Hold |
2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
2022-04-06 | Ripresa | Morgan Stanley | Underweight |
2021-12-17 | Iniziato | Goldman | Buy |
2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
2021-11-01 | Downgrade | Argus | Buy → Hold |
2021-07-27 | Ripresa | Truist | Buy |
2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-04-13 | Aggiornamento | Truist | Hold → Buy |
2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
2020-11-10 | Ripresa | Bernstein | Mkt Perform |
2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-09-29 | Iniziato | Berenberg | Buy |
2020-07-28 | Iniziato | Raymond James | Outperform |
2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
2020-02-27 | Iniziato | Barclays | Equal Weight |
2020-01-06 | Ripresa | Citigroup | Buy |
2019-12-13 | Aggiornamento | Argus | Hold → Buy |
2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
2019-10-17 | Ripresa | BofA/Merrill | Buy |
2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
2019-05-28 | Iniziato | Goldman | Buy |
2019-05-20 | Downgrade | Argus | Buy → Hold |
2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
2019-05-03 | Ripresa | JP Morgan | Overweight |
2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol-Myers Squibb Co. Borsa (BMY) Ultime notizie
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Benzinga
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
Benzinga
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks Investment Research
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Zacks Investment Research
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Zacks Investment Research
Why Bristol Myers Squibb Stock Is Sinking Today
The Motley Fool
Bristol-Myers Squibb Co. Azioni (BMY) Dati Finanziari
Bristol-Myers Squibb Co. (BMY) Reddito 2024
BMY ha riportato un ricavo (TTM) di $45.53 miliardi per il trimestre terminato il 2024-03-31, un -0.68% declino anno su anno.
Bristol-Myers Squibb Co. (BMY) Reddito netto 2024
BMY l'utile netto (TTM) è stato di -$6.15 miliardi per il trimestre terminato il 2024-03-31, un -184.09% diminuire anno su anno.
Bristol-Myers Squibb Co. (BMY) Flusso di cassa 2024
BMY ha registrato un flusso di cassa disponibile (TTM) di $12.51 miliardi per il trimestre conclusosi con 2024-03-31, un +12.89% aumento anno su anno.
Bristol-Myers Squibb Co. (BMY) Utile per azione 2024
L'utile per azione (TTM) di BMY è stato pari a -$3.10 per il trimestre terminato il 2024-03-31, un -190.38% declino anno su anno.
Bristol-Myers Squibb Co. Azioni (BMY) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Apr 01 '24 |
Option Exercise |
0.00 |
3,306 |
0 |
6,532 |
Lenkowsky Adam | EVP, Chief Commercial Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
15,016 |
0 |
13,859 |
LEUNG SANDRA | EVP, General Counsel |
Mar 10 '24 |
Option Exercise |
0.00 |
46,784 |
0 |
371,312 |
Plenge Robert M | EVP, Chief Research Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
9,143 |
0 |
15,182 |
Poole Ahn Amanda | EVP, Chief Human Resources |
Mar 10 '24 |
Option Exercise |
0.00 |
5,458 |
0 |
4,841 |
Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. |
Mar 10 '24 |
Option Exercise |
0.00 |
38,388 |
0 |
80,256 |
Holzer Phil M | SVP and Controller |
Mar 10 '24 |
Option Exercise |
0.00 |
5,520 |
0 |
14,916 |
Hoch Lynelle | President, Cell Therapy Org. |
Mar 10 '24 |
Option Exercise |
0.00 |
4,351 |
0 |
3,781 |
Gallman Cari | EVP, Corporate Affairs |
Mar 10 '24 |
Option Exercise |
0.00 |
2,761 |
0 |
2,655 |
BOERNER CHRISTOPHER S. | Chief Executive Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
54,638 |
0 |
129,769 |
Capitalizzazione:
|
Volume (24 ore):